648results about How to "Reduce side effects" patented technology

Electrochemical cells, and more specifically, rechargeable batteries comprising lithium anodes for use in water and / or air environments, as well as non-aqueous and non-air environments, are presented. In one embodiment, an electrochemical cell includes an anode comprising lithium and a multi-layered structure positioned between the anode and an electrolyte of the cell. A multi-layered structure can include at least a first single-ion conductive material layer (e.g., a lithiated metal layer), and at least a first polymeric layer positioned between the anode and the single-ion conductive material. The invention also can provide an electrode stabilization layer positioned within the electrode, i.e., between one portion and another portion of an electrode, to control depletion and re-plating of electrode material upon charge and discharge of a battery. Advantageously, electrochemical cells comprising combinations of structures described herein are not only compatible with environments that are typically unsuitable for lithium, but the cells may be also capable of displaying long cycle life, high lithium cycling efficiency, and high energy density.

The present invention relates to a miniature robotic device to be introduced, in the case of the heart, into the pericardium through a port, attach itself to the epicardial surface, and then, under the direct control of the user or physician, travel to the desired location for diagnosis or treatment.

Provided are: a compound represented by formula (I):(wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1 to 8 atoms in its main chain; L represents a hydrogen atom or a substituent; X represents amino which may have a substituent(s), or a heterocyclic group which contains at least one nitrogen atom and which may have a substituent(s); n represents 0 to 3, in which when n is 2 or more, a plurality of ring A's may be the same or different from one another); a salt thereof; an N-oxide form thereof; a solvate thereof, a prodrug thereof; and a medicament which includes those. The compound represented by formula (I) is capable of binding S1P receptors (in particular, EDG-1 and / or EDG-6), and useful for preventing and / or treating rejection in transplantation, autoimmune diseases, allergic diseases, etc.

Electrode protection in electrochemical cells, and more specifically, electrode protection in both aqueous and non-aqueous electrochemical cells, including rechargeable lithium batteries, are presented. In one embodiment, an electrochemical cell includes an anode comprising lithium and a multi-layered structure positioned between the anode and an electrolyte of the cell. A multi-layered structure can include at least a first single-ion conductive material layer (e.g., a lithiated metal layer), and at least a first polymeric layer positioned between the anode and the single-ion conductive material. The invention also can provide an electrode stabilization layer positioned within the electrode, i.e., between one portion and another portion of an electrode, to control depletion and re-plating of electrode material upon charge and discharge of a battery. Advantageously, electrochemical cells comprising combinations of structures described herein are not only compatible with environments that are typically unsuitable for lithium, but the cells may be also capable of displaying long cycle life, high lithium cycling efficiency, and high energy density.

The present invention provides novel methods and compositions for the treatment and prevention of headaches, vascular headaches, migraine headaches, cluster headaches, and migraine. One of the headaches, vascular headaches, migraine headaches, cluster headaches, and migraine treated by the methods and compositions of the invention is migraine.

A method of controlling charging of a battery (16) of a totally implantable auditory prosthesis and a control system (50) therefor. The method comprises determining a first charge related characteristic of the battery (16) such as the predetermined minimum amount of charge (58), and a second charge related battery characteristic such as the preset charge level or charge rate of the battery (16). The method further comprises detecting when a charge cycle of the battery (16) commences and monitoring where the charge level of the battery (16) is in relation to the first charge related battery characteristic when the charge cycle commences and adjusting the second charge related battery characteristic depending on the relationship between the charge level and the first charge related battery characteristic at the commencement of the charge cycle. The control system and method has the potential to increase the operational life of the battery (16).

The invention discloses a normal-temperature synthesis method for a polycarboxylic acid water-reducing agent, and belongs to the field of cement concrete water-reducing agents. The water-reducing agent is prepared by the following steps of: copolymerizing polyoxyethylene ether monomer or polyoxyethylene ester monomer a containing unsaturated double bonds, unsaturated monocarboxylic acid and derivative monomer thereof b, unsaturated dicarboxylic acid c and unsaturated sulfonic acid or salt monomer thereof d in aqueous solution under the action of an oxidation reduction initiator, and finally neutralizing the solution by using alkali solution to obtain the water-reducing agent. The reaction can be performed at room temperature by adopting an oxidation reduction initiating system, and the appropriate reaction temperature is between 5 and 30 DEG C; and the synthesis process does not need heating, so energy is saved, and high-temperature side reaction is effectively controlled. The prepared polycarboxylic acid high-performance water-reducing agent has the characteristics of high water-reducing rate and good collapse protecting performance. The water-reducing agent has wide application range, and the method has low production process requirement and is suitable for industrialized large-scale production.

Methods for synthesizing amorpha-4,11-diene synthase from isopentenyl pyrophosphate are provided. A first method comprises introducing into a host microorganism a plurality of heterologous nucleic acid sequences, each coding for a different enzyme in the mevalonate pathway for producing isopentenyl pyrophosphate. Amorpha-4,11-diene synthase is then produced using an optimized amorpha-4,11-diene synthase gene. The invention also provides nucleic acid sequences, enzymes, expression vectors, and transformed host cells for carrying out the methods.

A multi-component curable composition which is reactive upon admixing of the components and which comprises:(i) an acrylic polymer having acetoacetoxy functionality; and(ii) an acetoacetoxy functional derivative of a low molecular weight polyol; and(iii) a crosslinking component comprising at least one imine functional compound having an average of at least two imine groups per molecule which are reactive with acetoacetoxy functionality.

Please cancel the previous Abstract and insert the following new Abstract. The invention relates to an expandable intragastric balloon, for implantation into the stomach of a patient, to reduce the volume thereof for the treatment of obesity. Said balloon is provided with at least one first flexible pouch, capable of shifting from a folded position to an expanded position by introducing an inflation fluid into the first pouch, said expanded position giving a functional form to the balloon. Said balloon is characterized in that it comprises a ballasting means, for making said balloon substantially heavy to improve the positioning thereof in the stomach.

Process for synthesizing polyol fatty acid polyesters which includes the steps of reacting an excess of lower alkyl ester with polyol to esterify hydroxyl groups thereof and form polyol fatty acid polyester, separating at least a portion of the unreacted lower alkyl ester from the polyol fatty acid polyester, and recycling the separated unreacted lower alkyl ester for further reaction with polyol or partially esterified polyol. The recycled lower alkyl ester is substantially free of lower alkyl ester degradation reaction products, such as carbonyls and free fatty acids.

The invention relates to the field of polypeptides, in particular to a method for preparing semaglutide. The method has the advantages that Fmoc-Lys (Alloc)-OH protection amino acid is used as a raw material, de-protection is carried out by the aid of selected Pd (PPh3) 4, accordingly, operation procedures are simple, only 1-2 times of simple elimination reaction operation are required, each elimination reaction operation is carried out for 10-30 min, side reaction is prevented, the operation procedures are safe, and enlarged production can be facilitated; Boc-His (Boc)-OH. DCHA and Boc-His (Trt)-OH are used as raw materials in the procedures, and accordingly His racemization risks can be reduced to the greatest extent; special fragments are coupled, and accordingly the synthesis efficiency can be improved.

Graft copolymers as can comprise a wide range of graft side chains, available using atom transfer radical polymerization techniques.

An apparatus and method for subsequent optimization of radiosurgery and radiotherapy is provided. The invention includes administering a metalloporphyrin to the patient, and then creating a 3-dimensional mapping of tissue through use of PET or SPECT. Malignant and pre-malignant tissue has an affinity for the metalloporphyrin. During treatment, real-time images are also provided which are compared to the previous 3-dimensional mapping. Creation of the real-time images is also achieved through PET or SPECT wherein a metalloporphyrin is administered to the patient. Total administration of radiation is calculated by summing radiation from the metalloporphyrins and from the radiosurgery / radiotherapy. The amount of radiation delivered by the metalloporphyrins and by the radiosurgery / radiotherapy are adjustable based on a patient's response to the dual delivery.

A battery cell charging system, including a charger and a controller, for low-temperature (below about zero degrees Celsius) charging a lithium ion battery cell, the battery cell charging system includes: a circuit for charging the battery cell using an adjustable voltage charging-profile to apply a charging voltage and a charging current to the battery cell wherein the adjustable voltage charging-profile having: a non-low-temperature charging stage for charging the battery cell using a charging profile adapted for battery cell temperatures above about zero degrees Celsius; and a low-temperature charging stage with a variable low-temperature stage charging current that decreases responsive to a battery cell temperature falling below zero degrees Celsius.

Compositions and methods tor the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and / or antidepressant medications and also containing an NMPAR antagonist. The present invention is also directed to methods for the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and / or antipsychotic effective amounts.

Electrode protection in electrochemical cells, and more specifically, electrode protection in both aqueous and non-aqueous electrochemical cells, including rechargeable lithium batteries, are presented. In one embodiment, an electrochemical cell includes an anode comprising lithium and a multi-layered structure positioned between the anode and an electrolyte of the cell. A multi-layered structure can include at least a first single-ion conductive material layer (e.g., a lithiated metal layer), and at least a first polymeric layer positioned between the anode and the single-ion conductive material. The invention also can provide an electrode stabilization layer positioned within the electrode, i.e., between one portion and another portion of an electrode, to control depletion and re-plating of electrode material upon charge and discharge of a battery. Advantageously, electrochemical cells comprising combinations of structures described herein are not only compatible with environments that are typically unsuitable for lithium, but the cells may be also capable of displaying long cycle life, high lithium cycling efficiency, and high energy density.

This invention relates to: a novel use of GST-π and GST-π suppressing agents; an apoptosis-inducing agent containing as active components a drug that suppresses GST-π and a drug that suppresses autophagy; a medical composition containing said agent; and a method using said medical composition for treating diseases associated with abnormal apoptosis.

Methods for synthesizing isopentenyl pyrophosphate are provided. A first method comprises introducing into a host microorganism a plurality of heterologous nucleic acid sequences, each coding for a different enzyme in the mevalonate pathway for producing isopentenyl pyrophosphate. A related method comprises introducing into a host microorganism an intermediate in the mevalonate pathway and at least one heterologous nucleic acid sequence, each sequence coding for an enzyme in the mevalonate pathway necessary for converting the intermediate into isopentenyl pyrophosphate. The invention also provides nucleic acid sequences, enzymes, expression vectors, and transformed host cells for carrying out the methods.

The invention provides a combination comprising an ancillary compound and a compound having the formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R1-A-NR4— or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C═O, NR9(C═O) or 0(C═O) wherein R9 is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen, hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2; R2 is hydrogen; halogen; C1-4 alkoxy; or a C1-4 hydrocarbyl group optionally substituted by halogen, hydroxyl or C1-4 alkoxy; R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen, hydroxyl or C1-4 alkoxy.

A board-like division member is provided that extends in a vehicle body transverse direction so as to divide a portion of the engine room into an upper region and a lower region along in an engine room height direction. An engine is mounted downwardly of the division member. An exhaust treatment apparatus is mounted upwardly of the division member for treating exhaust gas from the engine. An air discharge portion is formed in a lateral face region of the hood which corresponds to a position of the division member in the engine room height direction. Air present inside the engine room is discharged to the outside through this air discharge portion.

A catalyst comprising at least one support, at least one element from groups 8, 9 or 10 of the periodic table, at least one element from group 14 of the periodic table, at least one element from group 13 of the periodic table, at least one alkali or alkaline-earth metal, and, optionally, at least one halogen in an amount in the range from 0 to 0.2% by weight with respect to the total catalyst weight, the catalyst being characterized in that the accessibility of the element from groups 8, 9 or 10 is more than 50%. The invention also concerns a process for preparing a catalyst and the use of the catalyst in a process for dehydrogenating paraffins containing 3 to 22 carbon atoms per molecule.

The present invention generally offers a system and a method that allows a vessel to treat water while providing corrosion inhibition. A nitrogen source produces nitrogen gas that may be pumped directly to, preferably but optionally, a venturi injector, or may first be pumped into an empty tank and then delivered to the injector means. Water being pumped through the injector via a transfer piping means comes into contact with the nitrogen, and dissolved oxygen in the water transfers to micro-fine nitrogen bubbles generated by the injector. The water and the micro-fine bubbles are pumped from the injector and into the tank, where the micro-fine bubbles float to the surface, and the oxygen is released into the tank's headspace. The deoxygenated water may be re-circulated through the system for additional deoxygenation or released from the tank into the surrounding waterways.

Catalysts that include at least one catalytically active element and one helper catalyst can be used to increase the rate or lower the overpotential of chemical reactions. The helper catalyst can simultaneously act as a director molecule, suppressing undesired reactions and thus increasing selectivity toward the desired reaction. These catalysts can be useful for a variety of chemical reactions including, in particular, the electrochemical conversion of CO2 or formic acid. The catalysts can also suppress H2 evolution, permitting electrochemical cell operation at potentials below RHE. Chemical processes and devices using the catalysts are also disclosed, including processes to produce CO, OH−, HCO−, H2CO, (HCO2)−, H2CO2, CH3OH, CH4, C2H4, CH3CH2OH, CH3COO−, CH3COOH, C2H6, O2, H2, (COOH)2, or (COO−)2, and a specific device, namely, a CO2 sensor.

The invention discloses a novel process for refining oil-tea camellia seed crude oil, which belongs to the technical field of grease refining in the fine and further processing of farm and sideline products. A process flow comprises the following steps: filtering the oil-tea camellia seed crude oil to eliminate impurities; performing a first low temperature acid reaction; performing low temperature alkali refining; removing soap; performing water washing after first acid adding; performing second water washing; and de-coloring and deodorizing the obtained product to obtain first-level oil-tea camellia seed oil. The novel process is characterized by improving the oil obtaining rate of refining, lowering production cost, improving product quality and stability and the like, and is used for refining the oil-tea camellia seed crude oil and refining rap oil, peanut oil and other vegetable oil.

Low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, solvates or hydrates thereof, along with one or more pharmaceutically acceptable excipient(s) are provided. The present invention also provides process of preparing such dosage forms and therapeutic methods of using such dosage forms. The low dose compositions 10 are designed to exhibit such bioavailability, which is effective in the treatment of NSAID indicated disorders particularly, which require long-term treatment regimens such as arthritis. Such compositions reduce the cost of therapy in diseases, which require long-term therapies, are easy to manufacture, and also result in the reduction of dose related side effects associated with nimesulide therapy.

Methods and systems are provided which maintain the positive and negative electrolyte pH and stability of a redox flow battery through the use of electrochemical rebalancing cells. The electrochemical cells may be activated by applying an electrical load to affect changes to the pH of the electrolytes. The use of the electrochemical cells improves long term performance stability redox flow batteries by decreasing and / or eliminating Fe(OH)3 precipitation formation.